In the era of combined antiretroviral therapy (cART), human immunodeficiency virus type 1 (HIV-1) is considered a chronic disease that specifically targets the brain and causes HIV-1-associated neurocognitive disorders (HAND). Endocannabinoids (eCBs) elicit neuroprotective and anti-inflammatory actions in several central nervous system (CNS) disease models, but their effects in HAND remain unknown. HIV-1 does not infect neurons, but produces viral toxins, such as transactivator of transcription (Tat), that disrupt neuronal calcium equilibrium and give rise to synaptodendritic injuries and cell death, the former being highly correlated with HAND. Consequently, we tested whether the eCBs N-arachidonoylethanolamine (anandamide/AEA) and 2-arachidonoyl-glycerol (2-AG) offer neuroprotective actions in a neuronal culture model. Specifically, we examined the neuroprotective actions of these eCBs on Tat excitotoxicity in primary cultures of prefrontal cortex neurons (PFC), and whether cannabinoid receptors mediate this neuroprotection. Tat-induced excitotoxicity was reflected by increased intracellular calcium levels, synaptodendritic damage, neuronal excitability, and neuronal death. Further, upregulation of cannabinoid 1 receptor (CB 1 R) protein levels was noted in the presence of HIV-1 Tat. The direct application of AEA and 2-AG reduced excitotoxic levels of intracellular calcium and promoted neuronal survival following Tat exposure, which was prevented by the CB 1 R antagonist rimonabant, but not by the CB 2 R antagonist AM630. Overall, our findings indicate that eCBs protect PFC neurons from Tat excitotoxicity in vitro via a CB 1 R-related mechanism. Thus, the eCB system possesses promising targets for treatment of neurodegenerative disorders associated with HIV-1 infection.
Introduction
Human immunodeficiency virus type 1 (HIV-1) infects the brain and, despite combined antiretroviral therapy (cART), many infected individuals suffer from HIV-1-associated neurocognitive disorders (HAND) (Antinori et al., 2007; Dore et al., 1999; Heaton et al., 2011; Sacktor et al., 2002) . HAND highly correlates with synaptodendritic damage, including dendritic simplification, axonal disruption, and synaptic loss (Ellis et al., 2007; Masliah et al., 1997) . The persistence of HAND in the era of cART has raised questions about the causes and treatment of HIV-1-related brain disorders and about the extent to which neuronal dysfunction and injury is reversible (Ellis et al., 2007) . It has been shown that upregulation of the endogenous cannabinoids (endocannabinoids; eCBs) anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) have protective properties in a variety of laboratory animal models of degenerative neurological disorders including multiple sclerosis, Parkinson's disease, and Alzheimer's disease (Pertwee, 2014; Scotter et al., 2010) . These, eCBs act predominantly via cannabinoid 1 (CB 1 ) and/or cannabinoid 2 (CB 2 ) receptors but also activate transient receptor potential (TRP) channels (Higgins et al., 2013; Kano, 2014; Yuan and Burrell, 2013) and/or other G-protein-coupled receptors (GPCRs) (Chevaleyre et al., 2006; Harkany et al., 2008; Ross et al., 2012) . AEA and 2-AG as well as their hydrolytic enzyme inhibitors (i.e. URB602, JZL184, AM5206) produce neuroprotective effects both in vitro (Chen et al., 2011; Naidoo et al., 2011) and in vivo (Lara-Celador et al., 2012; Naidoo et al., 2011) , but their effects in models of neuro-acquired immune deficiency syndrome (neuroAIDS) are little explored. The HIV-1 protein transactivator of transcription http://dx.doi.org/10. 1016/j.mcn.2017.07.003 (Tat) likely contributes to synaptodendritic injury observed in brains of HIV-1 infected individuals Valle et al., 2000) and has been shown to cause dendritic structural and functional defects in vitro (Bertrand et al., 2013; Bertrand et al., 2014; Fitting et al., 2014; Haughey et al., 1999; Haughey et al., 2001; Kruman et al., 1998) and in vivo (Carey et al., 2012; Fitting et al., 2013; Fitting et al., 2010; Hahn et al., 2013; Paris et al., 2015) . Tat activates both glutamatergic NMDA receptors (GluNs) (Aksenov et al., 2012; Fitting et al., 2014; Haughey et al., 2001; Li et al., 2008; Magnuson et al., 1995; Perez et al., 2001) and AMPA receptors (GluRs) (Longordo et al., 2006) , leading to increased excitability (Brailoiu et al., 2008; Fitting et al., 2015; Ngwainmbi et al., 2014) as well as increases in [Na + ] i , mitochondrial instability, and Ca 2 + influx Yu and Salter, 1998) , all of which eventually cause dendritic swellings (Bertrand et al., 2014; Fitting et al., 2014) . Interestingly, CB 1 receptor (CB 1 R) stimulation can limit glutamate-mediated synaptic excitation (Andre et al., 2010; Chevaleyre et al., 2006; Harkany et al., 2008; Marsicano et al., 2003; Monory et al., 2006; Rossi et al., 2011) . The goals of the present study were to determine whether AEA and 2-AG protect against synaptodendritic injury in an experimental model of HAND and to identify the receptor-related pathway mediating the neuroprotective effects of eCBs.
Materials and methods

Primary neuron culture
All experiments were approved by the University of North Carolina at Chapel Hill and conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Dissociated prefrontal cortex (PFC) primary neuron cultures were prepared from embryonic day 15-16 C57BL/6J mice as previously described . Brains of embryos were removed and the PFC was dissected, minced, and incubated (30 min, 37°C) with trypsin (2.5 mg/mL) and DNase (0.015 mg/mL) in neurobasal medium (Invitrogen) supplemented with B27 (Invitrogen), L-glutamine (0.5 mM; Invitrogen), glutamate (25 mM; Sigma-Aldrich) and an antibiotic mixture (Invitrogen). Tissues were triturated, filtered twice through 70 μm pore nylon mesh and then plated on MatTek glass bottom dishes (1 × 10 5 cells per dish, calcium experiments), on coverslips (3 × 10 5 cells per coverslip, electrophysiology and immunocytochemistry experiments), on 12-well plates (3 × 10 5 cells per well, morphology, time-lapse survival and Western blot experiments). The glass-bottom dishes and 12-well plates were coated with poly-L-lysine (Sigma-Aldrich), whereas coverslips for electrophysiology experiments were additionally coated with laminin (50 μg/mL, Corning). Neuron cultures were maintained in neurobasal medium supplemented with B27, 0.5 mM L-glutamine, 0.025 mM glutamate at 37°C in a humidified atmosphere containing 5% CO 2 . All experiments were performed on neuronal cultures at 7-12 days in vitro.
Immunocytochemistry
PFC neuronal cultures were fixed in 4% paraformaldehyde for 10 min, and then exposed to blocking buffer (1% normal goat serum, 4% bovine serum albumin, 0.4% Triton X-100 in PBS) for 1 h. Neuronal cultures were incubated with primary antibodies against glial fibrillary acidic protein (GFAP, rabbit, Millipore, AB5804; 1:500), MAP2ab (mouse, Millipore, MAB378; 1:500), and rat CB1R-NH (raised to amino acids 1-77 of the N-terminus; rabbit, 1:500; Tsou et al., 1998) , diluted in blocking buffer, overnight at 4°C. Primary antibodies were detected using appropriate secondary antibodies conjugated to either goat-antimouse Alexa 488 (Molecular Probes, O-6380, 1:1000) or goat-antirabbit Alexa 594 (Molecular Probes, A11012; 1:500). Secondary antibodies were diluted in blocking buffer and applied to the coverslips for 1 h at room temperature (RT). Coverslips were washed thoroughly with PBS and mounted using ProLong Gold (Molecular Probes, P36930). Confocal immunofluorescent images were acquired using a Zeiss LSM T-PMT laser scanning confocal microscope equipped with a 63× oil immersion objective and configured to an Axio Observer Z.1 microscope (Zeiss, Thornwood, NY). Images were collected using Zen 2010 blue Edition software (Carl Zeiss, Inc., Thornwood, NY) and created from multiple z-stacks taken through the thickness of the section, then converted into orthogonal projection images. Adobe Photoshop CS6 Extended 13.0 software (Adobe Systems, Inc.; San Jose, CA) was used to edit the images.
Calcium imaging
Live fluorescence cell imaging was conducted on living PFC neurons using a Zeiss Axio Observer Z.1 inverted microscope (Carl Zeiss, Inc., 20× objective) with an automated, computer-controlled stage encoder with environmental control (37°C, 95% humidity, 5% CO 2 ). (Grynkiewicz et al., 1985) . The cytoplasm of neuronal perikarya was manually outlined as the region of interest (ROI). Due to the heterogeneity among neurons, the mean ± SEM values for changes in [Ca 2 + ] i were computed comparing individual neurons before and at specific intervals during treatment using a repeated measures analysis of variance (ANOVA). Quantitative analyses of [Ca 2 + ] i levels in neuronal perikarya were performed on 10-20 neurons per treatment per experiment; at least three independent experiments were conducted for each treatment group.
Electrophysiology recordings
Recordings of synaptic responses of PFC pyramidal neurons were conducted on our PFC primary cell cultures as previously described (Fitting et al., 2015; Ngwainmbi et al., 2014) . Coverslips were transferred to a submersion-type recording chamber (Warner Instruments, Hamden, CT) on a Siskiyou 4080P fixed-stage system (Grants Pass, OR) and perfused with artificial cerebrospinal fluid (aCSF) containing (in mM): 128 NaCl, 10 D-glucose, 26 NaHCO 3 , 2 CaCl 2 , 2 MgSO 4 , 3 KCl, and 1.25 NaH 2 PO 4. The aCSF was heated to 30 to 33°C with an inline heater (Warner SC-20, Hamden, CT) at a rate of 2 to 3 mL per min. PFC pyramidal neurons were identified visually by using an Axio Examiner A1 microscope (Zeiss, Thornwood, NY) equipped with a 40× water-immersion objective coupled with an infrared differential interference contrast and an integrated Dodt gradient camera system. Whole-cell patch-clamp recordings from PFC neurons were established using a MultiClamp 700B amplifier (Axon Instruments, Union City, CA). Membrane current and potential signals were digitized and analyzed with Digidata 1550A and pClamp 10.0 systems (Molecular Devices, Sunnyvale, CA). Patch pipettes of~5 MΩ were pulled with a PC-10 puller (Narishige, Greenvale, NY). Patch pipettes were filled with (in mM): 115 K-gluconate, 10 HEPES, 5 KCl, 2 MgCl 2 , 2 Mg-ATP, 2 Na 2 -ATP, 0.4 Na 2 GTP and 10 Na 2 -phosphocreatine (pH 7.33). Spontaneous currents were recorded at resting membrane potential (~75 ± 5 mV). Inward currents are considered excitatory amino acid currents (EPSCs), whereas the outward currents (inhibitory postsynaptic currents, IPSCs) were blocked by bath application of bicuculline (10 μM). Drugs were administered by bath application. Synaptic currents were collected for 5 min for each experimental condition. Access resistance (< 25 MΩ) was regularly monitored during recordings, and cells were rejected if resistance changed > 15% during the experiment. If the access resistance increased during the course of the experiment and caused significant reductions in the synaptic current amplitudes, efforts were made to improve access (such as applying additional suction or slight positive pressure). If this correction failed the experiment was discontinued. Spontaneously occurring synaptic currents were filtered at 2 kHz, and digitized at 10 kHz using Digidata 1550A. Off-line analysis of synaptic currents was performed using the Minianalysis software (Version 6.0.8; Synaptosoft, Decatur, GA). Synaptic currents were screened automatically using an amplitude threshold of 3 pA. Events were then visually screened to ensure that the analysis was not distorted by changes in noise level or by membrane fluctuations. If the background noise increased during the recording the data from that cell were discarded. Quantitative analyses were performed on 14-26 neurons per treatment.
Dendritic morphology
PFC neuronal dendritic morphology was assessed using a Zeiss Axio Observer Z.1 inverted microscope (Carl Zeiss, Inc.) with an automated, computer-controlled stage encoder with environmental control (37°C, 95% humidity, 5% CO 2 ). PFC neurons were grown in 12-well plates. For each well, 6 non-overlapping fields were randomly selected using a 20× objective. For purposes of quantification, PFC neurons that displayed normal morphology (Kreitzer, 2009) were selected from each field at the beginning of the experiment. Pyramidal PFC neurons were identified in digital images of each field based on their distinctive morphology. Images were recorded at 30 min intervals for 24 h using an automated, computer-controlled stage encoder and Zen 2011 software (Carl Zeiss, Inc.). Both qualitative and quantitative assessments of dendrite morphology were made. Three dendrites of one neuron were randomly chosen and monitored for dendritic swelling over the 24 h assay period. Dendritic data for each neuron was averaged. Dendritic swelling was defined when the dendrite displayed aberrant features, such as beading and/or varicosity occurring along proximal and/or distal segments. An abrupt, 2-fold increase in the diameter of the main axis of the dendrite (typically ≥3 μm diameter) that did not coincide with a branch-point was used as criterion for beading or varicosity formation. Dendritic swellings were repeatedly counted per 40-60 μm dendritic lengths prior to and every 30 min after treatment exposure on the same neuron using time-lapse imaging. Repeated measures ANOVA was performed on 6 neurons per treatment per experiment; at least three independent experiments for each treatment.
Neuronal survival
PFC neuronal survival was assessed over a three day time period using a Zeiss Axio Observer Z.1 inverted microscope (Carl Zeiss, Inc.) with an automated, computer-controlled stage encoder with environmental control (37°C, 95% humidity, 5% CO 2 ). Time-lapse studies were conducted as previously described (Zou et al., 2011) . Briefly, PFC neurons were grown in 12-well plates. For each well, 6 non-overlapping fields were selected with identifying 6-8 neurons in each field based on distinctive morphology. Time-lapse images were recorded at 1 h intervals for 60 h using the stage encoder and Zen 2011 software (Carl Zeiss, Inc.). Neuronal death was assessed using rigorous morphological criteria, including neurite disintegration, loss of phase brightness and fragmentation of the cell body. Results are presented as mean percentage of surviving neurons relative to pretreatment numbers. Repeatedmeasure ANOVA was performed on 6-8 neurons per treatment per experiment; at least three independent experiments for each treatment.
Cell lysate preparation, protein assay and Western blot analysis
Cell extracts were prepared by lysing cells on ice in an appropriate volume of ice-cold RIPA Lysis and Extraction buffer (G-Bioscience) with protease inhibitor cocktail (Amresco, Ohio). Lysates were then centrifuged at 10,000g for 10 min at 4°C. BCA protein assay was used to determine sample protein concentration. Protein lysates were suspended in Laemmli buffer (1:5) and denatured at 95°C for 3 min. Equal amounts of protein (10 μg/lane) was resolved in 10% SDS-PAGE at a 150 V for 1 h using BioRad Protean 3 mini apparatus. Electrophoretic transfer of proteins from the gel to nitrocellulose membranes was carried out in 10 mM CAPS buffer with 0.01% SDS, pH 11, overnight at 0-4°C at 20 V using a Bio-Rad Trans-Blot Cell equipped with a cooling coil. Blots were rinsed with Tris-buffered saline (TBS), incubated with blocking buffer (5% nonfat dry milk plus 5% normal goat serum in TBS) at RT for 1 h followed by incubation with affinity-purified anti-CB 1 (rabbit polyclonal; Cayman; 1: 1000 dilution for 3 h) at RT, rinsed 2× with TBS, and then incubation with anti β-Actin (anti-mouse from Cell Signaling; 1: 1000) for 3 h, rinsed 3× with TBS (TBS with 0.1% Tween 20) and incubated with horseradish peroxidase-coupled anti-rabbit and anti-mouse IgG sequentially (with 1× TBS rinse in between) for 1 h at RT. Immunoreactive bands were detected by ECL reaction (Amersham) from the blot using BioRad Gel Doc XR + system and image acquiring software (Image Lab ver. 5.1). Densitometric analysis was carried out using a modified version (version 1.59) of the Scion Image software (Scion Corporation).
Treatments
Treatments included HIV-1 Tat 1-86 (10-100 nM; ImmunoDiagnostics; clade B), the eCB N-arachidonoylethanolamine (anandamide/AEA, 3 nM-1 μM, Tocris, Ellisville, MO) and 2-arachidonoyl glycerol (2-AG, 3 nM-1 μM, Tocris, Ellisville, MO), CB 1 R antagonist rimonabant (3 nM-1 μM, Tocris, Ellisville, MO) and the CB 2 R antagonist AM630 (3-30 nM, Tocris, Ellisville, MO). Reagent stocks were stored at − 80°C for less than one month. Endocannabinoid concentrations were chosen based on preliminary experiments (data not shown) and based on previous studies that assessed the protective effects of cannabinoids in different disease models, including NMDAinduced increases in [Ca 2 + ] i (Liu et al., 2009; Zhuang et al., 2005) , AMPA-induced excitotoxicity (Kokona and Thermos, 2015) , gp120-induced synaptic loss (Kim et al., 2011) , and gp120-induced dopaminergic neuronal damage (Hu et al., 2013) . Tat concentrations were chosen from the range that elicited functional deficits in glia and neurons similar to those occurring in HIV-1, and that are considered to reflect levels seen under pathological conditions (El-Hage et al., 2008; El-Hage et al., 2005; Kruman et al., 1998; Nath et al., 1999; Perry et al., 2010; Singh et al., 2004) . Even though the concentration of Tat in the cerebral spinal fluid (CSF) has been reported at 1.14 nM (16 ng/mL) (Westendorp et al., 1995) , higher concentration of Tat could be attainable locally during HIV-1 infection within close proximity of acutely replicating HIV-infected cells as Tat is released by HIV-1 infected cells (Sabatier et al., 1991) . For the calcium imaging, dendritic morphology and neuronal survival experiments, eCBs were added 3 h prior to Tat treatment with readings being taken from the soma for all calcium imaging studies and from the dendrites for the morphological experiments. Inhibitors/antagonists were added to the culture 30 min prior to eCB treatment, and for the duration of the experiment. Pretreatment concentrations were chosen to maximally block treatments based on preliminary explorative assessments conducted prior to the main experiments (data not shown). For the electrophysiology experiments, treatments were added acutely to the bath solution and recordings were taken 5 min after treatment application.
Statistical analyses
Data were analyzed using ANOVAs (SYSTAT 11.0 for Windows, SYSTAT) followed by post hoc tests, using Bonferroni's correction as needed. In repeated measures ANOVAs for the within-subjects factors (i.e., comparing multiple time points), violations of compound symmetry were addressed by using the Greenhouse-Geisser degrees of freedom correction factor (Greenhouse and Geisser, 1959) . For electrophysiology experiments statistical analyses were performed using paired Student's t-tests as needed. An alpha level of p < 0.05 was considered significant for all statistical tests used. Data are expressed as the mean ± SEM from at least three independent experiments.
Results
Concentration-dependent HIV-1 Tat-induced toxicity in cultured PFC neurons
In the post-cART era, focus on the PFC in neuroAIDS has acquired increased importance, because these patients exhibit major cortical cognitive deficiencies in addition to subcortical deficits (Hardy and Vance, 2009; Scott et al., 2011) . Specifically, HIV-1 patients display problems in executive function, memory consolidation, and attention (Cysique et al., 2004; Garvey et al., 2009; Heaton et al., 2011) . Because most dysfunctions observed in neuroAIDS during post-cART era seem to be related to impaired PFC function, we have focused our investigation on PFC in in vitro primary dissociated neuronal cultures (Fig. 1) . Experiments were performed on PFC cultures at 7-12 days in vitro with neurons forming neuronal networks (Fig. 1A) . Immunohistochemistry indicated primary the presence of neurons, assessed by microtubuleassociated protein 2 immunostaining (MAP2ab, green), as well as the presence of some astrocytes, assessed by glial fibrillary acidic protein (GFAP, red; Fig. 1B ). In these PFC neuronal cultures, bath application of Tat indicated a concentration-dependent increase of [Ca 2 + ] i levels and decreased neuronal survival (Fig. 2) . A significant dysregulation of cytosolic Ca 2 + was noted for Tat concentrations equal or higher than 30 nM over a 20 min time period (p < 0.05; Fig. 2A-A″) . Tat induced increased neuronal death in a concentration-related manner over a 60 h time period (Fig. 2B-B″ synaptic loss (Kim et al., 2011) , and gp120-induced dopaminergic neuronal damage (Hu et al., 2013) . However, no systematic study has investigated the neuroprotective effects of AEA and 2-AG against Tatinduced neuronal damage. Therefore, we examined whether AEA and 2-AG will prevent the Tat-induced excitotoxicity and neuronal injury/ death observed in Tat-treated PFC neuronal cultures (Fig. 3) . Pretreating PFC neuronal cultures with different concentrations of AEA or 2-AG followed by application of 100 nM Tat 3 h later, resulted in significant alterations of Tat-induced increases in [Ca 2 + ] i . Specifically, 30 nM AEA (p < 0.05) but not 3 nM AEA (Fig. 3A) , and 3 nM 2-AG (p < 0.05) but not 30 nM 2-AG (Fig. 3B) ] i levels within the first minute after 100 nM Tat application, which was blocked by the CB 1 R antagonist rimonabant (30 nM), but not by the CB 2 R antagonist AM630 (30 nM) (Fig. 3A') . Further, 30 nM AEA prevented Tat-induced neuronal death. This effect was mediated by CB 1 Rs, but not CB 2 Rs (Fig. 3A" ). Similar effects were noted for 3 nM 2-AG preventing elevation in Tat ] i level and neuronal survival were noted following treatments of the different concentrations of eCB ligands alone or CBR antagonists alone (data not shown). We further were interested in the eCB + Tat effects on dendritic morphology as synaptodendritic damage is the best known correlate of HAND (Masliah et al., 1997) . Thus, our observations that 30 nM AEA and 3 nM 2-AG significantly reduced Tat-induced dendritic swellings and varcosities (p < 0.05; Fig. 3C ] i levels, and neuronal death, via a CB 1 R-mediated mechanism.
AEA and 2-AG prevent Tat-induced effects on sEPSCs
To determine the functional effects of Tat and eCBs on our PFC neuronal cultures, we explored the effects of Tat, AEA, 2-AG, and rimonabant on glutamatergic neurotransmission by assessing sEPSCs (Fig. 4) . Representative traces of sEPSCs are shown for before and after 100 nM Tat application (Fig. 4A and D, respectively) , before and after 1 μM AEA ± 100 nM Tat or 1 μM 2-AG ± 100 nM Tat applications ( Fig. 4A′ and D′, respectively) , and before and after 1 μM rimonabant ± eCBs ± 100 nM Tat applications (Fig. 4A″ and D″, respectively). A significant Tat effect was noted, with Tat increasing mean frequency of sEPSCs compared to control (p < 0.05; Fig. 4B, E) , whereas no effect was noted for the mean amplitude of sEPSCs (Fig. 4C,  F) . When pretreating PFC neuronal cultures with 1 μM AEA or 1 μM 2-AG via 5 min bath application, the mean frequency was significantly decreased (p < 0.05; Fig. 4B′, E′) , while additionally preventing a significant Tat-induced increase in sEPSC frequency (p < 0.05 vs. control). No significant effects were noted for AEA ± Tat or 2- ] i level during the final 5 min (from 15 to 20 min) indicated a significant concentration-dependent increase by Tat, with a significant effect for 100 nM Tat. (B) Phase images of PFC neuronal cultures of control and Tat conditions assessing neuronal survival in a time-lapse study over a 60 h time period. A single neuron followed for the control condition shows neuronal survival over 60 h (white arrowheads, top row), whereas a single neuron followed for the 100 nM Tat condition died at ≥24 h (white arrowheads, bottom row) although many adjacent neurons remain alive and occasionally exhibit movement during this time period. (B′) Treatment of 100 nM Tat for 60 h significantly reduced the survival of PFC neurons, whereas 30 nM Tat was not significantly different from control. (B″) Average neuronal survival during the final 6 h (from 54 to 60 h), indicated a significant concentration-dependent decrease by Tat, with a significant effect for 100 nM Tat. Statistical significance was assessed by ANOVA followed by Bonferroni's post hoc test; *p < 0.05 versus control, # p < 0.05 versus Tat 100 nM; arrows indicate the onset of treatment (three independent experiments, 10-20 neurons per experiment). Images are the same magnification. Scale bar = 50 μm.
AG ± Tat on the mean amplitude of sEPSCs (Fig. 4C′, F′) . Further, the eCBs protective effects against Tat-induced excitability on sEPSC frequency were blocked in the presence of rimonabant (p < 0.05; Fig 4B″,  4E″) . No effects were noted on sEPSC frequency or amplitude when exposing PFC neuronal cultures with rimonabant alone (data not shown). For the mean amplitude of sEPSCs, no significant effects were noted for any of the conditions (Fig. 4C″, F″) .
Tat exposure increases CB 1 R protein expression
To determine Tat whether alters CBR protein expression in our PFC neuronal cultures, Western blot and immunohistochemistry analyses were conducted (Fig. 5) . Western blot analyses indicated that 100 nM Tat increased CB 1 R protein levels in a time-dependent manner, whereas no effects were noted for CB 2 R protein expression (p < 0.05; Fig. 5A ).
Additionally, immunohistochemistry of PFC pyramidal neurons stained for MAP2ab (green) and CB 1 R (red) demonstrated CB 1 R staining localized in the soma, dendrites and growth cones of neurons, suggesting that the cannabinoid machinery for this receptor is present in our PFC primary neuronal culture model (Fig. 5B ).
Discussion
Using an in vitro mouse PFC neuronal culture model, the present study demonstrated that AEA and 2-AG provide neuroprotection against Tat-induced toxicity through the reduction of Tat-induced increases in intracellular calcium, synaptodendritic damage, cell excitability, and neuronal death. As each of these eCBs activates CB 1 Rs and CB 2 Rs (Pertwee et al., 2010) , we used a pharmacological approach to determine whether either or both of these receptors mediate the ] i levels over a 20 min assessment period was blocked by rimonabant but not AM630 (30 min prior 2-AG application). (B″) Tatinduced neuronal death assessed in a timelapse study over 60 h was significantly decreased by 3 nM 2-AG pretreatment and significantly blocked by rimonabant but not AM630 at the 60 h time point. (C) Timedependent effects of 100 nM Tat on dendritic morphology were noted with neurons displaying increased focal dendritic swellings/varicosities (arrowhead) over 24 h, which was prevented by 30 nM AEA and 3 nM 2-AG pretreatment. Statistical significance was assessed by ANOVA followed by Bonferroni's post hoc test; *p < 0.05 versus control, # p < 0.05 versus Tat 100 nM; arrows indicate the onset of treatment (three independent experiments, 6 neurons per experiment). Images are the same magnification. Scale bar = 20 μm. Rim: rimonabant, AM6: AM630.
protective effects of eCBs. Rimonabant, but not AM630, blocked the protective effects of AEA and 2-AG on measures of Tat-induced toxicity, suggesting that CB 1 Rs play a necessary role in the process. Whereas CB 1 Rs are among the most highly expressed GPCRs on neurons Mukhopadhyay et al., 2002) and CB 2 Rs are mostly expressed on immune and glial cells (Bouaboula et al., 1993; Maresz et al., 2007; Munro et al., 1993) , recent findings suggest the possible presence of CB 2 Rs in some neuronal populations (Onaivi et al., 2012; Quraishi and Paladini, 2016; Zhang et al., 2014) , specifically in brain stem and ventral tegmental area neurons (Zhang et al., 2016) . Importantly, several in vivo and in vitro studies have also indicated neuroprotective effects of cannabinoids from HIV-1 protein toxicity via CB 2 Rs (Avraham et al., 2014; Hu et al., 2013; Kim et al., 2011; Raborn and Cabral, 2010) . However, the protective effects of cannabinoid-induced CB 2 R activation are regulated through glial cells and macrophages (Hu et al., 2013; Raborn and Cabral, 2010) . For example, in a mouse model of Parkinson's disease, WIN55,212-2 elicited protective effects against nigrostriatal cell loss through an increase in the density of CB 2 Rs in reactive microglia, which regulate glial cell function and homeostasis of surrounding neurons (Price et al., 2009) . Notably, our PFC neuronal cultures (that predominantly consisted of neurons with < 7.5% glia) expressed very low levels of CB 2 R protein in the absence or presence of Tat, whereas CB 1 R protein levels increased with Tat exposure in a time-dependent manner up to two-fold (Fig. 5) . CB 1 Rs are known for their neuromodulatory activity and are abundantly expressed in neurons of different brain regions such as the cortex, hippocampus, basal ganglia, and cerebellum (Matsuda et al., 1990) . In different pathological conditions the modified expression of CB 1 Rs and/ or CB 2 R has been correlated with the prognosis of the symptoms (Miller and Devi, 2011) . In neuropathic pain and multiple sclerosis, for example, increases in CBR expression is associated with reductions of symptoms and/or dampened disease progression, suggesting a neuroprotective role (Pertwee, 2009) . A recent HIV-1 human study, conducting immunohistological analysis in the cerebral cortex and white matter of HIV-1-infected patients showed an increase in CB 1 R and CB 2 R expression in HIV encephalitis brains compared to brains of HIV negative cases (Cosenza-Nashat et al., 2011) . Our findings of increased CB 1 R expression following Tat exposure are consistent with these observations in humans. Tat induces neurotoxicity by activating glutamatergic NMDA receptors (Aksenov et al., 2012; Haughey et al., 2001; Li et al., 2008; Longordo et al., 2006; Magnuson et al., 1995; Perez et al., 2001 ) and by increasing [Ca 2 + ] i levels via inositol 1,4,5-trisphosphate (IP 3 )-regulated and/or ryanodine-regulated pools Haughey et al., 1999; Lipton, 1994; Nath and Geiger, 1998) . Endocannabinoids have been suggested to protect CNS neurons in different disease models of toxicity (Chen et al., 2011; Lara-Celador et al., 2012; Monory et al., 2006; Naidoo et al., 2011; Rossi et al., 2011) . A previous study indicated that NMDA-receptor-mediated release of [Ca 2 + ] i , via effects on ryanodine receptor (RyR) sensitive channels, was reduced through WIN55-212-2-mediated CB 1 R activation (Hampson et al., 2011) . Activation of CB 1 Rs by eCBs inhibits adenylyl cyclase synthesis via G i , which reduces the phosphorylation of RyR resulting in a reduction of ] i release in response to synaptic activation of NMDA receptors (Hampson et al., 2011) . Consistent with our findings in the present study that AEA and 2-AG are protective against Tat-induced increases in [Ca 2 + ] i levels, synaptodendritic damage, cell excitability, and neuronal death, a striatal cell culture model has demonstrated that these eCBs enhanced Gα i/o and Gβγ signaling and can lead to increased total CB 1 R levels (Laprairie et al., 2014) . Interestingly, the protective concentration of 2-AG in our study was much lower (3 nM) compared to AEA (30 nM), probably due to the fact that 2-AG has greater efficacy at CB 1 Rs and CB 2 Rs compared to that of AEA (Gonsiorek et al., 2000; Mechoulam et al., 1995; Sugiura et al., 2000) . Additionally differences were noted in the survival data in which rimonabant, as well as AM630, appeared to partially block the protective effects of 2-AG, but not of AEA, over the 60 h time period. It has been shown that specifically high concentrations of AM630 can also antagonize CB 1 Rs (Murataeva et al., 2012) . It should also be pointed out that in our calcium, electrophysiology, and dendritic morphology experiments we are not able to distinguish between those neurons that will survive and those that will die. However, by examining functional and morphological injury at different time points, this study demonstrates that eCBs are protective against Tat-induced damage at all time points; thus, making it possible to identify therapeutic targets to prevent or possibly reverse structural/ functional/behavioral deficits. Rescuing the synapse through defined mechanisms may enable injured neurons to survive and regain function.
The eCB system has been recognized as a major contributor to maintain brain homoeostasis. Disturbances of different neurotransmitter systems have been reported in HAND, including alterations in glutamatergic neurotransmission (Ernst et al., 2010; Ferrarese et al., 2001) , serotonergic systems (Murray, 2003; Schroecksnadel et al., 2007) , dopaminergic circuits (Berger and Arendt, 2000; Gelman et al., 2006; Nath et al., 2000; Wang et al., 2004) and GABAergic systems (Buzhdygan et al., 2016; Gelman et al., 2012) . The Tat-induced increases in excitability, with the enhancement of the sEPSC frequency without affecting their amplitude, suggest a stimulatory effect on glutamate release, but not on vesicles refilling, supporting previous reports (Brailoiu et al., 2008) . Interestingly, by decreasing sEPSC frequency, 2-AG and AEA prevented the Tat-induced increase in sEPSC frequency. It has been shown that mice lacking fatty acid amid hydrolase (FAAH), and thus expressing elevated brain levels of AEA (Rossi et al., 2011) , preserve disease-induced sEPSC alterations via a CB 1 R-related mechanism. CB 1 Rs are expressed on presynaptic neurons in many brain regions, where they regulate both excitatory and inhibitory neurotransmission (Kano et al., 2009; Mackie, 2005; Matsuda et al., 1990; Onaivi et al., 2012) . Moreover, cannabinoid receptor agonists inhibit glutamatergic and GABAergic neurotransmission in the PFC (Auclair et al., 2000; Bellocchio et al., 2010; Kano et al., 2009; Kovacs et al., 2012; Lee et al., 2015; Ohno-Shosaku and Kano, 2014; Piomelli, 2003) . By these means, eCBs appear to control the excitatory actions of Tat on the glutamatergic system by decreasing its stimulatory effect on glutamate release but not on vesicle refilling. Further studies are necessary to assess this finding in more detail.
Conclusion
The present study demonstrates that eCBs are protective against HIV-1 Tat-induced excitotoxicity and neuronal injury, which has been shown to highly correlate with HAND. Due to the rapid degradation of AEA and 2-AG by their respective catabolic enzymes FAAH (Cravatt et al., 1996; Deutsch and Chin, 1993) , and monoacylglycerol lipase (MAGL) (Blankman et al., 2007; Dinh et al., 2002) , future studies should focus on selective inhibitors of those enzymes. Highly selective inhibitors of FAAH and MAGL show neuroprotective, anti-inflammatory, antinociceptive and anxiolytic effects (Ahn et al., 2009; Booker et . CB 1 R protein expression is increased by Tat exposure. (A) Western blot analyses indicated increased CB 1 R protein levels after 100 nM Tat treatment in a time-course dependent manner, whereas no effects were noted for CB 2 R protein expression. (B) Immunohistochemistry was conducted on PFC neurons to identify regional and cellular distribution of CB 1 R. Cells were stained for MAP2ab (green) and endogenous CB 1 receptor (red). CB 1 R are localized in the soma, dendrites and growth cones of PFC neurons, indicating that the cannabinoid machinery is present in our PFC primary cell culture model. Statistical significance was assessed by ANOVA followed by Bonferroni's post hoc test; *p < 0.05 versus control, # p < 0.05 versus 30 min Tat 100 nM (three independent experiments). Images are the same magnification. Scale bar = 20 μm.
